Abciximab (Reopro) ACS Medication

Question 1

Classification:

Answer 1

• GP IIb/IIIa inhibitor

Question 2

Action:

Answer 2

• Prevents aggregation of platelets by inhibiting the integrin GP IIb/IIIa receptor

Question 3

Indications:

Answer 3

• UA/NSTEMI patients undergoing planned/emergent percutaneous coronary artery intervention

Question 4

Adverse Effects:

Answer 4

• Bleeding from GI tract
• Internal bleeding
• Intracranial hemorrhage
• Hypotension
• Stroke
• Anaphylactic shock

Question 5

Contraindications:

Answer 5

• Bleeding from any source
• Severe uncontrolled HTN
• Surgery/ trauma within the previous 6 weeks
• Stroke within previous 30 days
• Renal failure
• Thrombocytopenia
• Intracranial mass

Question 6

Dosage (UA/NSTEMI w/ planned PCI within 24 hours):

Answer 6

• 0.25 mg/kg IV, IO (10-60 mins before procedure)
  -Then 0.125 mcg/kg/min IV, IO infusion for 12-24 hours

Question 7

Dosage (Percutaneous Coronary Intervention Only):

Answer 7

• 0.25 mg/kg IV, IO
  -10 mcg/min IV, IO infusion